Cantor Fitzgerald将Novavax2025年的EPS预测值提高到2.32美元, Cantor Fitzgerald raises Novavax's 2025 EPS forecast to $2.32 amid strong revenue, while lowering Vaxcyte's to ($5.73) on wider loss.

Cantor Fitzgerald将Novavax的2025财政年度EPS预测值提高到232美元,理由是收入强劲,净差值为正值,尽管该公司错过了收入估计数,在股本上出现了负回报。 Cantor Fitzgerald raised Novavax's FY2025 EPS forecast to $2.32, citing strong revenue and a positive net margin, though the company missed earnings estimates and posted a negative return on equity. 股票交易额7.11美元,贝塔和混合分析师评级高。 The stock trades at $7.11 with a high beta and mixed analyst ratings. Vaxcyte报告的损失比预期的要大,促使Cantor Fitzgerald将2025财政年度EPS预测降低到5.73美元,而TD Cowen则保持了“Buy”评级和50美元价格目标,并列举了其输出细菌疾病蛋白质基疫苗的潜力。 Vaxcyte reported a wider-than-expected loss, prompting Cantor Fitzgerald to lower its FY2025 EPS forecast to ($5.73), while TD Cowen maintained a "Buy" rating and $50 price target, citing potential in its pipeline of protein-based vaccines for bacterial diseases.